JDM  Vol.4 No.3 , August 2014
Treatment Satisfaction with Insulin Glargine in Insulin-Naïve Type 2 Diabetes Patients—A Hong Kong Based Registry
Abstract: Objective: To evaluate patient satisfaction with insulin glargine. Design: Multicentre observational registry. Data were collected at baseline/inclusion visit, and 12 and 24 weeks. Setting: Physicians in Hong Kong, who managed type 2 diabetes patients and had >5 years’ experience in using insulin glargine. Patients: People with type 2 diabetes, new to insulin, aged 18 - 75 years, who were previously being treated with ≤3 oral antidiabetes drugs (OAD) and had HbA1c > 7%, and in whom the physicians had chosen to prescribe glargine for the first time. Main outcome measures: Treatment satisfaction assessed by Diabetes Treatment Satisfaction Questionnaire (DTSQs), glycaemic control (fasting blood glucose and HbA1c) and adverse events. Results: Between April 2010-October 2011, 41 patients completed the study. Average duration of diabetes and OAD therapy was 7.8 ± 8.0 years and 6.7 ± 7.4 years, respectively. The global DTSQs treatment satisfaction scores improved from 20.9 at baseline to 28.4 (p < 0.05) at the end of 24 weeks insulin glargine treatment. Analysis of DTSQs scores showed a decrease in perceived frequency of hyperglycaemia (4.1 to 1.9, p < 0.001) and hypoglycemia (2.2 to 1.5, p = 0.079). Perceived convenience (0.60, p < 0.025) and flexibility (0.9, p < 0.009) were also improved from baseline. Reduction in mean HbA1c (10.2% ± 2.2% to 7.0% ± 1.0%) and fasting blood glucose (10.9 ± 4.0 mmol/L to 6.4 ± 1.8 mmol/L) from baseline to study termination was significant (p < 0.05). Almost half (48.7%) of patients achieved HbA1c ≤ 7.0%, while 26.0% patients had FBG < 5.6 mmol/L. In total, 9 (22.0%) patients experienced at least one hypoglycemia event; there were no reports of severe hypoglycaemia. Conclusions: Despite a small number of subjects completed in this study, the study demonstrated clearly that the addition of insulin glargine to OAD therapy in diabetes management improved treatment satisfaction and perceived frequency of hyper-and hypoglycaemia together with glycaemic control close to recommended target without severe side-effects in this cohort of patients in Hong Kong.
Cite this paper: Chan, W. , Ngai, W. and Tong, P. (2014) Treatment Satisfaction with Insulin Glargine in Insulin-Naïve Type 2 Diabetes Patients—A Hong Kong Based Registry. Journal of Diabetes Mellitus, 4, 232-241. doi: 10.4236/jdm.2014.43033.

[1]   Davidson, J.A. (2004) Treatment of the Patient with Diabetes, Importance of Maintaining Target HbA(1c) Levels. Current Medical Research and Opinion, 20, 1919-1927.

[2]   American Diabetes Association (2006) Standards of Medical Care in Diabetes—2006. Diabetes Care, 29, S4-S42.

[3]   Unnikrishnan, A.G., Wangnoo, S.K., Joshi, S.R., et al. (2012) Physician Perceptions and Practices in Management of Diabetes in India, Results from the IMPROVE Control Program. Indian Journal of Endocrinology and Metabolism, 16, S428-S429.

[4]   Eliasson, B., Cederholm, J., Nilsson, P. and Gudbjornsdottir, S. (2005) The Gap between Guidelines and Reality, Type 2 Diabetes in a National Diabetes Register 1996-2003. Diabetic Medicine, 22, 1420-1426.

[5]   Liberopoulos, E.N., Tsouli, S., Mikhailidis, D.P. and Elisaf, M.S. (2006) Preventing Type 2 Diabetes in High Risk Patients, an Overview of Lifestyle and Pharmacological Measures. Current Drug Targets, 7, 211-228.

[6]   Turner, R.C., Cull, C.A., Frighi, V. and Holman, R.R. (1999) Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus, Progressive Requirement for Multiple Therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Journal of the American Medical Association, 281, 2005-2012.

[7]   Hirsch, I.B. (2005) Insulin Analogues. The New England Journal of Medicine, 352, 174-183.

[8]   Pearson, J. and Powers, M.A. (2006) Systematically Initiating Insulin, the Staged Diabetes Management Approach. The Diabetes Educator, 32, 19S-28S.

[9]   Polonsky, W.H., Fisher, L., Guzman, S., Villa-Caballero, L. and Edelman, S.V. (2005) Psychological Insulin Resistance in Patients with Type 2 Diabetes, the Scope of the Problem. Diabetes Care, 28, 2543-2545.

[10]   Peyrot, M., Rubin, R.R., Lauritzen, T., et al. (2005) Resistance to Insulin Therapy among Patients and Providers, Results of the Cross-National Diabetes Attitudes, Wishes, and Needs (DAWN) Study. Diabetes Care, 28, 2673-2679.

[11]   Hayes, R.P., Fitzgerald, J.T. and Jacober, S.J. (2008) Primary Care Physician Beliefs about Insulin Initiation in Patients with Type 2 Diabetes. International Journal of Clinical Practice, 62, 860-868.

[12]   Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., et al. (2000) Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of Long-Acting Human Insulin Analog Glargine, NPH Insulin, and Ultralente Human Insulin and Continuous Subcutaneous Infusion of Insulin Lispro. Diabetes, 49, 2142-2148.

[13]   HOE.901/2004 Study Investigators Group (2003) Safety and Efficacy of Insulin Glargine (HOE 901) versus NPH Insulin in Combination with Oral Treatment in Type 2 Diabetic Patients. Diabetic Medicine, 20, 545-551.

[14]   Riddle, M.C., Rosenstock, J. and Gerich, J. (2003) The Treat-to-Target Trial, Randomized Addition of Glargine or Human NPH Insulin to Oral Therapy of Type 2 Diabetic Patients. Diabetes Care, 26, 3080-3086.

[15]   Rosenstock, J., Schwartz, S.L., Clark Jr., C.M., Park, G.D., Donley, D.W. and Edwards, M.B. (2001) Basal Insulin Therapy in Type 2 Diabetes, 28-Week Comparison of Insulin Glargine (HOE 901) and NPH Insulin. Diabetes Care, 24, 631-636.

[16]   Yki-Jarvinen, H., Kauppinen-Makelin, R., Tiikkainen, M., V?h?talo, M., Virtamo, H., Nikkil?, K., et al. (2006) Insulin Glargine or NPH Combined with Metformin in Type 2 Diabetes: The LANMET Study. Diabetologia, 49, 442-451.

[17]   Houlden, R., Ross, S., Harris, S., Yale, J.F., Sauriol, L. and Gerstein, H.C. (2007) Treatment Satisfaction and Quality of Life Using an Early Insulinization Strategy with Insulin Glargine Compared to an Adjusted Oral Therapy in the Management of Type 2 Diabetes, the Canadian Insight Study. Diabetes Research and Clinical Practice, 78, 254-358.

[18]   Holman, R.R., Thorne, K.I., Farmer, A.J., Davies, M.J., Keenan, J.F., Paul, S., et al. (2007) Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. The New England Journal of Medicine, 357, 1716-1730.

[19]   Rosenstock, J., Sugimoto, D., Strange, P., Stewart, J.A., Soltes-Rak, E., Dailey, G., et al. (2006) Triple Therapy in Type 2 Diabetes, Insulin Glargine or Rosiglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin in Insulin-Na?ve Patients. Diabetes Care, 29, 554-559.

[20]   Ringborg, A., Cropet, C., J?nsson, B., Gagliardino, J.J., Ramachandran, A. and Lindgren, P. (2009) Resource Use Associated with Type 2 Diabetes in Asia, Latin America, the Middle East and Africa, Results from the International Diabetes Management Practices Study (IDMPS). International Journal of Clinical Practice, 63, 997-1007.

[21]   Bradley, C. and Lewis, K.S. (1990) Measures of Psychological Well-Being and Treatment Satisfaction Developed from the Responses of People with Tablet-Treated Diabetes. Diabetic Medicine, 7, 445-451.

[22]   Bradley, C. The Diabetes Treatment Satisfaction Questionnaire, DTSQ. eHopadagtpmidrapC.

[23]   Anderson, R.T., Skovlund, S.E., Marrero, D., Levine, D.W., Meadows, K., Brod, M., et al. (2004) Development and Validation of the Insulin Treatment Satisfaction Questionnaire. Clinical Therapeutics, 26, 565-578.

[24]   Bradley, C., Todd, C., Gorton, T., Symonds, E., Martin, A. and Plowright, R. (1999) The Development of an Individualized Questionnaire Measure of Perceived Impact of Diabetes on Quality of Life: The ADDQoL. Quality of Life Research, 8, 79-91.

[25]   Wee, H.L., Tan, C.E., Goh, S.Y. and Li, S.C. (2006) Usefulness of the Audit of Diabetes-Dependent Quality-of-Life (ADDQoL) Questionnaire in Patients with Diabetes in a Multi-Ethnic Asian Country. Pharmacoeconomics, 24, 673682.

[26]   Grootenhuis, P.A., Snoek, F.J., Heine, R.J. and Bouter, L.M. (1994) Development of a Type 2 Diabetes Symptom Checklist: A Measure of Symptom Severity. Diabetic Medicine, 11, 253-261.

[27]   Pouwer, F., Snoek, F.J., van der Ploeg, H.M., Ader, H.J. and Heine, R.J. (2000) The Well-Being Questionnaire, Evidence for a Three-Factor Structure with 12 Items (W-BQ12). Psychological Medicine, 30, 455-462.

[28]   Gershater, M.A., Frid, A. and Apelqvist, J. (2009) Treatment Satisfaction with Insulin Glargine in Patients with Diabetes Mellitus in a University Hospital Clinic in Sweden. European Diabetes Nursing, 6, 17-22.

[29]   Swinnen, S.G., Dain, M.P., Aronson, R., Davies, M., Gerstein, H.C., Pfeiffer, A.F., et al. (2010) A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily with Insulin Detemir Twice-Daily in Patients with Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs. Diabetes Care, 33, 1176-1178.

[30]   Hajos, T.R., Pouwer, F., de Grooth, R., Holleman, F., Twisk, J.W.R., Diamant, M., et al. (2012) The Longitudinal Association between Glycaemic Control and Health-Related Quality of Life Following Insulin Therapy Optimisation in Type 2 Diabetes Patients. A Prospective Observational Study in Secondary Care. Quality of Life Research, 21, 1359-1365.

[31]   Bretzel, R.G., Nuber, U., Landgraf, W., Owens, D.R., Bradley, C. and Linn, T. (2008) Once-Daily Basal Insulin Glargine versus Thrice-Daily Prandial Insulin Lispro in People with Type 2 Diabetes on Oral Hypoglycaemic Agents (APOLLO), an Open Randomised Controlled Trial. The Lancet, 371, 1073-1084.

[32]   Janka, H.U., Plewe, G., Riddle, M.C., Kliebe-Frisch, C., Schweitzer, M.A. and Yki-Jarvinen, H. (2005) Comparison of Basal Insulin Added to Oral Agents versus Twice-Daily Premixed Insulin as Initial Insulin Therapy for Type 2 Diabetes. Diabetes Care, 28, 254-259.

[33]   Little, S., Shaw, J. and Home, P. (2011) Hypoglycemia Rates with Basal Insulin Analogs. Diabetes Technology & Therapeutics, 13, S53-S64.

[34]   Mullins, P., Sharplin, P., Yki-Jarvinen, H., Riddle, M.C. and Haring, H.U. (2007) Negative Binomial Meta-Regression Analysis of Combined Glycosylated Hemoglobin and Hypoglycemia Outcomes across Eleven Phase III and IV Studies of Insulin Glargine Compared with Neutral Protamine Hagedorn Insulin in Type 1 and Type 2 Diabetes Mellitus. Clinical Therapeutics, 29, 1607-1619.

[35]   Pan, C.Y., Sinnassamy, P., Chung, K.D. and Kim, K.W. (2007) Glargine versus NPH Insulin Therapy in Asian Type 2 Diabetes Patients. Diabetes Research and Clinical Practice, 76, 111-118.

[36]   Blicklé, J.F., Hancu, N., Piletic, M., Profozic, V., Shestakova, M., Dain, M.P., et al. (2009) Insulin Glargine Provides Greater Improvements in Glycaemic Control vs. Intensifying Lifestyle Management for People with Type 2 Diabetes Treated with OADs and 7-8% A1c Levels. The TULIP Study. Diabetes, Obesity and Metabolism, 11, 379-386.

[37]   Schiel, R. and Müller, U.A. (2007) Efficacy and Treatment Satisfaction of Once-Daily Insulin Glargine plus One or Two Oral Antidiabetic Agents versus Continuing Premixed Human Insulin in Patients with Type 2 Diabetes Previously on Long-Term Conventional Insulin Therapy: The Switch Pilot Study. Experimental and Clinical Endocrinology & Diabetes, 115, 627-633.

[38]   Schreiber, S.A. and Haak, T. (2007) Insulin Glargine Benefits Patients with Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Treatment, an Observational Study of Everyday Practice in 12,216 Patients. Diabetes, Obesity & Metabolism, 9, 31-38.

[39]   Tamemoto, H., Ikoma, A., Saitoh, T., Ishikawa, S.E. and Kawakami, M. (2007) Comparison of Once-Daily Glargine Plus Sulfonylurea with Twice-Daily 70/30 Aspart Premix in Insulin-Naive Japanese Patients with Diabetes. Diabetes Technology & Therapeutics, 9, 246-253.

[40]   Davies, M., Lavalle-González, F., Storms, F. and Gomis, R. (2008) Initiation of Insulin Glargine Therapy in Type 2 Diabetes Subjects Suboptimally Controlled on Oral Antidiabetic Agents: Results from the AT.LANTUS Trial. Diabetes, Obesity and Metabolism, 10, 387-399.